Guardant Health, Inc. Aktie News

Guardant Health stock rocketed Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA)'s Medical Devices Advisory Committee has strongly recommended FDA approval of the company's Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who ar...

Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet today to review the premarket approval (PMA) application for ShieldTM,...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. William Blair 44th Annual Growth Stock Conference in Chicago Presentation on Tuesday, June 4 at 3:20 p.m. CT / 4:20 p.m. ET Jefferies Global Healthcare Conference in New York Presentation on Wednesday, J...

DALLAS--(BUSINESS WIRE)--Trinity Industries, Inc. (“Trinity” or the “Company”) today announced that it intends to offer (the “Offering”) an additional $200.0 million aggregate principal amount of its 7.750% Senior Notes due 2028 (the “Additional Notes”). Trinity intends to use the net proceeds from the Offering, if consummated, together with cash on hand and/or borrowings under its corporate re...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Union's In Vitro Diagnostic Regulation (IVDR 2017/746). The certification from TÜV SÜD Product Service is for tumor mutation profiling in patients with any solid cancerous tumor and for companion diagno...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 215,601 shares of its common stock to 94 new non-executive employees and non-qualified stock option awards to purchas...